Similarly, Talzenna (generic name talazoparib) was tested on patients with advanced, HER2-negative breast cancer in the EMBRACA phase 3 clinical trial in 2017 (Litton et al. 2018). This evidence concerns the gene ERBB2 and breast carcinoma.